Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
Figure 1
Characterization of the PBS-injected and the liver-specific scAAV-FXRα2 or scAAV-FXRα4 transduced FXR knock-out mice.
Hepatic FXR gene expression (A) and protein (B) levels in total PBS-injected FXR knock-out mice versus stably transduced scAAV-FXRα2 or scAAV-FXRα4 FXR knock-out mice. Dotted line in (A) represents WT FXR expression levels. Plasma ASAT (C) and ALAT (D) levels were not altered in the AAV-treated mice compared to PBS-injected controls. (E) Cholesterol distribution in FPLC-separated lipoprotein fractions. Values are presented in box-and-whisker plots or averages (n = 4–6 animals per group). *p<0.05 vs. PBS.